BREAKING: Pfizer Is Now Developing Twice-a-Day Pills You’ll Take WITH Your Vaccines!

Think forced vaccines were bad?

Think never ending booster shots were bad?

Well, it’s about to get worse.

A lot worse.

Get ready for a new “twice a day” pill that you will take in addition to the vaccine and the never ending boosters!

Developed, of course, by your friendly “scientists” at Pfizer.

Hey, what could go wrong?

TRENDING: Fauci Says 100,000 More Will Die By December; People Need To Get Vaccinated!

Except everything.

If you think I’m taking the jab, you’re dead wrong….but if you think I’m taking a twice-a-day pill from Pfizer you’ve done lost your mind!

But it’s real, take a look at this…

Albert Bourla is the Chariman and CEO of Pfizer….swell guy, I’m sure!

This coin is a symbol of President Trump’s victory and success. This item sells for $39.95 on Amazon. Today’s special promotion is offering a massive discount on this item. President Trump 2020 Coin (Gold & Silver Plated) – Claim 1 Free OR Claim a Discount + Free Shipping Get Your Coin HERE Or Click on the image above.

And here’s what he just Tweeted:

And here’s the Press Release that accompanied his Tweet with all the nasty details of how Pfizer wants you gulping down their pills twice a day…..(for the rest of your life?):

First Participant Dosed in Phase 2/3 Study of Oral Antiviral Candidate in Non-Hospitalized Adults with COVID-19 Who Are at Low Risk of Severe Illness

New York, N.Y., September 1, 2021 – Pfizer Inc. (NYSE:PFE) today shared that the first participant has been dosed in a pivotal Phase 2/3 clinical trial to evaluate the safety and efficacy of PF-07321332 – an investigational orally administered protease inhibitor antiviral therapy designed specifically to combat COVID-19 – in non-hospitalized, symptomatic adult participants who have a confirmed diagnosis of SARS- CoV-2 infection and are not at increased risk of progressing to severe illness, which may lead to hospitalization or death.

The randomized, double-blind trial will enroll approximately 1,140 participants, who will receive PF- 07321332/ritonavir or placebo orally every 12 hours for five days.

Protease inhibitors, like PF-07321332, are designed to block the activity of the main protease enzyme that the coronavirus needs to replicate. Co-administration with a low dose of ritonavir is expected to help slow the metabolism, or breakdown, of PF-07321332 in order for it to remain in the body for longer periods of time at higher concentrations, thereby working continuously to help combat the virus. Ritonavir has previously been used in combination with other antivirals to similarly inhibit metabolism.

This study is part of a global clinical development program, consisting of multiple ongoing and planned clinical trials to evaluate this early-intervention, outpatient therapeutic candidate for potential use in a broad population of patients. The first registrational trial in this program, a pivotal Phase 2/3 study of PF- 07321332/ritonavir in non-hospitalized, symptomatic adult participants who have been diagnosed with SARS-CoV-2 infection and are at increased risk of progressing to severe illness, began enrollment in July 2021.

If successful, PF-07321332/ritonavir has the potential to address a significant unmet medical need, providing patients with a novel oral therapy that could be prescribed at the first sign of infection, without requiring hospitalization.

About Pfizer: Breakthroughs That Change Patients’ Lives



Leave a Reply

Your email address will not be published. Required fields are marked *